| 1. |
- Dunnett, S. B, et al.
(författare)
-
Preface
- 2017
-
Ingår i: Functional Neural Transplantation IV Translation to Clinical Application, Part B. - 0079-6123. - 9780128138793 ; 231
-
Bokkapitel (övrigt vetenskapligt/konstnärligt)
|
|
| 2. |
- Kokaia, Z., et al.
(författare)
-
Transplantation of reprogrammed neurons for improved recovery after stroke
- 2017
-
Ingår i: Functional Neural Transplantation IV Translation to Clinical Application, Part B. - : Elsevier. - 0079-6123. - 9780128138793 ; 231, s. 245-263
-
Bokkapitel (refereegranskat)abstract
- Somatic cells such as fibroblasts, reprogrammed to induced pluripotent stem cells, can be used to generate neural stem/progenitor cells or neuroblasts for transplantation. In this review, we summarize recent studies demonstrating that when grafted intracerebrally in animal models of stroke, reprogrammed neurons improve function, probably by several different mechanisms, e.g., trophic actions, modulation of inflammation, promotion of angiogenesis, cellular and synaptic plasticity, and neuroprotection. In our own work, we have shown that human skin-derived reprogrammed neurons, fated to cortical progeny, integrate in stroke-injured neuronal network and form functional afferent synapses with host neurons, responding to peripheral sensory stimulation. However, whether neuronal replacement plays a role for the improvement of sensory, motor, and cognitive deficits after transplantation of reprogrammed neurons is still unclear. We conclude that further preclinical studies are needed to understand the therapeutic potential of grafted reprogrammed neurons and to define a road map for their clinical translation in stroke.
|
|
| 3. |
- Dunnett, S., et al.
(författare)
-
Preface
- 2017
-
Ingår i: Functional Neural Transplantation IV Translation to Clinical Application, Part A. - 0079-6123. ; 230
-
Bokkapitel (övrigt vetenskapligt/konstnärligt)
|
|
| 4. |
- Kirkeby, A., et al.
(författare)
-
Strategies for bringing stem cell-derived dopamine neurons to the clinic : A European approach (STEM-PD)
- 2017
-
Ingår i: Functional Neural Transplantation IV Translation to Clinical Application, Part A. - : Elsevier. - 0079-6123. - 9780128117385 ; 230, s. 165-190
-
Bokkapitel (refereegranskat)abstract
- The treatment of Parkinson's disease (PD) has for over 50 years relied on dopaminergic therapies that are highly effective especially in the early years of the condition, but ultimately are limited by the development of side effects that relate to the nonphysiological stimulation of dopamine receptors including in nonstriatal areas. Targeted regenerative therapies designed to restore specifically the lost dopaminergic innervation of the striatum would therefore represent a major advance in treating PD. Transplantation of human fetal ventral midbrain tissue to the striatum of PD patients has provided proof-of-principle that such an approach can provide long-term clinical benefits with a reduced dependency on any oral dopaminergic agents. However, fetal tissue is associated with several ethical and logistical problems and therefore does not represent a realistic route to the clinical treatment of PD in the future. As a result, alternative cell sources have been explored and the methods for producing authentic midbrain dopaminergic neurons from pluripotent cells have now advanced to a stage which makes it possible to efficiently and reproducibly produce DA progenitors at a much higher purity than can be obtained from human fetal tissue. A stem cell-based therapy for PD therefore has the potential to circumvent many of the problems currently associated with fetal tissue grafting. Here, we describe the challenges faced and the strategies that have been pursued in our European effort to bring a human embryonic stem cell (hESC)-derived dopamine cell product to clinical trial for PD.
|
|
